Neurogene Inc. (NASDAQ:NGNE) CFO Christine Mikail Cvijic Sells 4,501 Shares of Stock

Neurogene Inc. (NASDAQ:NGNE) CFO Christine Mikail Cvijic sold 4,501 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $16.94, for a total value of $76,246.94. Following the completion of the transaction, the chief financial officer now owns 72,343 shares in the company, valued at $1,225,490.42. The trade was a 5.86 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Neurogene Stock Performance

Shares of Neurogene stock opened at $16.87 on Tuesday. Neurogene Inc. has a 52-week low of $14.42 and a 52-week high of $74.49. The stock’s 50-day simple moving average is $17.66 and its 200 day simple moving average is $30.02.

Hedge Funds Weigh In On Neurogene

Several large investors have recently modified their holdings of NGNE. Samsara BioCapital LLC boosted its holdings in Neurogene by 35.4% in the 4th quarter. Samsara BioCapital LLC now owns 1,717,127 shares of the company’s stock worth $39,254,000 after buying an additional 449,337 shares during the period. RTW Investments LP boosted its holdings in shares of Neurogene by 18.9% in the fourth quarter. RTW Investments LP now owns 1,350,256 shares of the company’s stock worth $30,867,000 after acquiring an additional 215,000 shares during the period. Redmile Group LLC grew its position in shares of Neurogene by 36.9% in the fourth quarter. Redmile Group LLC now owns 1,319,763 shares of the company’s stock valued at $30,170,000 after purchasing an additional 355,416 shares in the last quarter. Casdin Capital LLC raised its stake in shares of Neurogene by 146.9% during the 4th quarter. Casdin Capital LLC now owns 1,295,361 shares of the company’s stock valued at $29,612,000 after purchasing an additional 770,745 shares during the period. Finally, FMR LLC lifted its holdings in Neurogene by 912.4% during the 3rd quarter. FMR LLC now owns 731,801 shares of the company’s stock worth $30,706,000 after purchasing an additional 659,515 shares in the last quarter. Hedge funds and other institutional investors own 52.37% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. BMO Capital Markets dropped their price target on Neurogene from $60.00 to $45.00 and set an “outperform” rating on the stock in a report on Wednesday, November 20th. HC Wainwright reissued a “buy” rating and issued a $55.00 price target on shares of Neurogene in a report on Monday, November 25th. Finally, William Blair restated an “outperform” rating on shares of Neurogene in a report on Tuesday, November 19th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Neurogene has a consensus rating of “Buy” and an average price target of $60.83.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.